Orexo AB, a leading pharmaceutical company headquartered in Sweden, focuses on developing innovative treatments for addiction and pain management. Founded in 1995, Orexo has established a strong presence in Europe and North America, with a commitment to addressing unmet medical needs through advanced drug delivery technologies.
The company’s core products, including Zubsolv, a sublingual film for opioid dependence, exemplify its unique approach to patient care. Orexo's dedication to research and development has positioned it as a key player in the pharmaceutical industry, with notable achievements in improving treatment outcomes for patients struggling with addiction. With a robust pipeline and a focus on sustainable growth, Orexo continues to make significant strides in enhancing the quality of life for individuals facing complex health challenges.
-1 vs industry average
Orexo’s score of 37 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Orexo?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Orexo's reported carbon emissions
Orexo, headquartered in SE, reported a total of approximately 1.54 million kg CO2e for 2024. This encompassed approximately 312,000 kg CO2e from Scope 1, approximately 366,000 kg CO2e from Scope 2, and approximately 859,000 kg CO2e from Scope 3 emissions. In 2023, Orexo's total emissions stood at approximately 2.01 million kg CO2e, comprising approximately 273,000 kg CO2e from Scope 1, approximately 3.79 million kg CO2e from Scope 2, and approximately 13.54 million kg CO2e from Scope 3. For the year 2022, Orexo's total emissions were approximately 2.27 million kg CO2e. This included approximately 284,000 kg CO2e from Scope 1, approximately 4.05 million kg CO2e from Scope 2, and approximately 15.73 million kg CO2e from Scope 3. Regarding reduction initiatives, Orexo reported a 3% decrease in Scope 1 and 2 emissions in 2023 compared to the 2022 baseline, attributed to reduced emissions from sales force travel.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Orexo’s Climate Goals (2030 & 2050)
2 goals2023
3% reduction in Scope 1
With 2022 as the base year, Scope 1 and 2 emissions decreased by 3 percent in 2023, driven by lower emissions from sales travel by the sales…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Orexo
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project